41 related articles for article (PubMed ID: 26385641)
21. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
22. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
23. Treatment of fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ
Cancer; 2009 Jul; 115(13):2824-36. PubMed ID: 19402170
[TBL] [Abstract][Full Text] [Related]
24. Advances in the treatment of chronic lymphocytic leukemia.
Lamanna N
Curr Hematol Malig Rep; 2006 Mar; 1(1):43-8. PubMed ID: 20425331
[TBL] [Abstract][Full Text] [Related]
25. Treatment of relapsed or refractory chronic lymphocytic leukemia.
Veliz M; Pinilla-Ibarz J
Cancer Control; 2012 Jan; 19(1):37-53. PubMed ID: 22143061
[TBL] [Abstract][Full Text] [Related]
26. Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience.
Boogaerts MA
Hematol J; 2004; 5 Suppl 1():S31-7. PubMed ID: 15079151
[TBL] [Abstract][Full Text] [Related]
27. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.
Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherrill B; Ruiz-Soto R; Kaye JA; Hamadani M
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):199-207. PubMed ID: 25445467
[TBL] [Abstract][Full Text] [Related]
28. Future prospects for fludarabine-containing regimens in the treatment of hematological cancers.
Hillmen P
Hematol J; 2004; 5 Suppl 1():S76-86. PubMed ID: 15079156
[TBL] [Abstract][Full Text] [Related]
29. Advances in the treatment of chronic lymphocytic leukemia.
Lamanna N
Curr Oncol Rep; 2005 Sep; 7(5):333-8. PubMed ID: 16091193
[TBL] [Abstract][Full Text] [Related]
30. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia.
Fürstenau M; Hallek M; Eichhorst B
Haematologica; 2019 Nov; 104(11):2144-2154. PubMed ID: 31585959
[TBL] [Abstract][Full Text] [Related]
31. Advances in the therapy of chronic lymphocytic leukemia.
Johnson AJ; Mone AP; Abhyankar V; Byrd JC
Curr Opin Hematol; 2003 Jul; 10(4):297-305. PubMed ID: 12799536
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Picardi P; Cairoli R; Montillo M
Biologics; 2015; 9():75-86. PubMed ID: 26425075
[TBL] [Abstract][Full Text] [Related]
33. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
Flowers CR; Brown JR; Rosenthal H; Stock W; Katzen HI; Cohen JB; Sinha R; Lakhanpal S; Leis JF; Waller EK; Jaye DL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):694-8. PubMed ID: 26385641
[TBL] [Abstract][Full Text] [Related]
34. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.
Leporrier M
Hematol J; 2004; 5 Suppl 1():S10-9. PubMed ID: 15079149
[TBL] [Abstract][Full Text] [Related]
35. Current and developing chemotherapy for CLL.
Montserrat E
Med Oncol; 2002; 19 Suppl():S11-9. PubMed ID: 12180487
[TBL] [Abstract][Full Text] [Related]
36. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
